Does clinical inertia vary by personalized a1c goal? a study of predictors and prevalence of clinical inertia in a U.S. managed-care setting

Endocrine Practice

Volumn 22, Issue 2, 2016, Pages 123-135

  Lin, Jay ^a   Zhou, Steve ^b   Wei, Wenhui ^b   Pan, Chunshen ^c   Lingohr Smith, Melissa ^a   Levin, Philip ^d  

^a Novosys Health   (United States)

^b Sanof US   (United States)

^c Pro Unlimited Inc   (United States)

^d MODEL Clinical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HEMOGLOBIN A1C; STATIN (PROTEIN); GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ARTICLE; DEMENTIA; HEART FAILURE; HEART INFARCTION; HUMAN; MENTAL DISEASE; MIDDLE AGED; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OBSERVATIONAL STUDY; PREVALENCE; RETROSPECTIVE STUDY; RISK FACTOR; THORACIC AORTA ANEURYSM; VASCULAR DISEASE; ADOLESCENT; BLOOD; CLINICAL COMPETENCE; COMPLICATION; DIABETES MELLITUS, TYPE 2; FEMALE; GENERAL PRACTITIONER; HEALTH INSURANCE; HEALTH PERSONNEL ATTITUDE; MALE; MOTIVATION; PERSONALIZED MEDICINE; STANDARDS; STATISTICS AND NUMERICAL DATA; TIME TO TREATMENT; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ATTITUDE OF HEALTH PERSONNEL; CLINICAL COMPETENCE; DIABETES MELLITUS, TYPE 2; FEMALE; GOALS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; PHYSICIANS, PRIMARY CARE; PRECISION MEDICINE; PREVALENCE; RETROSPECTIVE STUDIES; TIME-TO-TREATMENT; UNITED STATES; YOUNG ADULT;

EID: 84979849231     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP15868.OR     Document Type: Article

References (37)

1. Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Diabetes. 1997;46:271-286.
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) UK Prospective Diabetes Study (UKPDS) Group. Lancet.1998;352:837-853.
3. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977-986.
4. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-393.
5. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Longterm results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23 Suppl 2:B21-B29.
6. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117.
7. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care. 2003;26:1902-1912.
8. Mitchell BD, Vietri J, Zagar A, Curtis B, Reaney M. Hypoglycaemic events in patients with type 2 diabetes in the United Kingdom: associations with patient-reported outcomes and self-reported HbA1c. BMC Endocr Disord. 2013;13:59.
9. Snoek FJ, Skovlund SE, Pouwer F. Development and validation of the insulin treatment appraisal scale (ITAS) in patients with type 2 diabetes. Health Qual Life Outcomes. 2007;5:69.
10. Wild D, von Maltzahn R, Brohan E, Christensen T, Clauson P, Gonder-Frederick L. A critical review of the literature on fear of hypoglycemia in diabetes: implications for diabetes management and patient education. Patient Educ Couns. 2007;68:10-15.
11. Alvarez Guisasola F, Tof? Povedano S, Krishnarajah G, Lyu R, Mavros P, Yin D. Hypoglycemic symptoms, treatment satisfaction, adherence and their associations with glycemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes Obes Metab. 2008;10 Suppl 1:25-32.
12. Ross SA, Tildesley HD, Ashkenas J. Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes. Curr Med Res Opin. 2011;27 Suppl 3:13-20.
13. Briscoe VJ, Davis SN. Hypoglycemia in type 1 and type 2 diabetes: physiology, pathophysiology, and management. Clin Diabetes. 2006;24:115-121.
14. Leiter LA, Yale J, Chiasson J, Harris S, Kleinstiver P, Sauriol L. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management. Can J Diabetes. 2005;29:186-192.
15. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012;29:682-689. 16. Healthy People 2020 medical product safety objectives. Office of Disease Prevention and Health Promotion, US Department of Health and Human Services, web site. Available at: http://www.healthypeople.gov/2020/topics-objectives/topic/medical-product-safety/objectives. Accessed February 5, 2015.
16. Fu H, Curtis BH, Xie W, Festa A, Schuster DP, Kendall DM. Frequency and causes of hospitalization in older compared to younger adults with type 2 diabetes in the United States: a retrospective, claims-based analysis. J Diabetes Complications. 2014;28:477-481.
17. Geller AI, Shehab N, Lovegrove MC, et al. National estimates of insulin-related hypoglycemia and errors leading to emergency department visits and hospitalizations. JAMA Intern Med. 2014;174:678-686.
18. Insulin action. Joslin Diabetes Center web site. Available at: http://www.joslin.org/info/insulin-action.html. Accessed March 11, 2015.
19. Ilag, LL, Kerr L, Malone JK, Tan MH. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison. Clin Therap. 2007;7:1254-1270.
20. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35: 1364-1379.
21. Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care. 2008;31:20-25.
22. Fritsche A, Larbig M, Owens D, H?ring HU; GINGER study group. Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study. Diabetes Obes Metab. 2010;12:115-123.
23. Pearson T. Glucagon as a treatment of severe hypoglycemia: safe and efficacious but underutilized. Diabetes Educ. 2008;34:128-134.
24. Eby EL, Wang P, Curtis BH, et al. Cost, healthcare resource utilization, and adherence of individuals with diabetes using U-500 or U-100 insulin: a retrospective database analysis. J Med Econ. 2013;16:529-538.
25. Friedman JH. Stochastic gradient boosting. Comput Stat Data Anal. 2002;38:367-378.
26. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
27. Fleming TR, Harrington DP. Counting Processes and Survival Analysis. New York, NY: John Wiley & Sons; 1991.
28. Glucagon for injection (rDNA origin) prescribing information. Eli Lilly and Company web site. Available at: http://pi.lilly.com/us/rglucagon-ppi.pdf. Accessed March 19, 2015.
29. GlucaGen (glucagon [rDNA origin] for injection) prescribing information. Novo Nordisk web site. Available at: http://www.novo-pi.com/glucagenhypokit.pdf. Accessed March 19, 2015.
30. American Diabetes Association. Standards of Medical Care in Diabetes-2014. Diabetes Care. 2014; 37 Suppl 1:S14-S80.
31. Frier BM. Hypoglycaemia in the diabetic adult. Baillieres Clin Endocrinol Metab. 1993;7:757-777.
32. Khunti K, Fisher H, Paul S, Iqbal M, Davies MJ, Siriwardena AN. Severe hypoglycaemia requiring emergency medical assistance by ambulance services in the East Midlands: a retrospective study. Prim Care Diabetes. 2013;7:159-165.
33. Krnacova V, Kubena A, Macek K, Bezdek M, Smahelova A, Vlcek J. Severe hypoglycaemia requiring the assistance of emergency medical services-frequency, causes and symptoms. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2012;156:271-277.
34. Parsaik AK, Carter RE, Myers LA, et al. Populationbased study of hypoglycemia in patients with type 1 diabetes mellitus requiring emergency medical services. Endocr Pract. 2012;18:834-841.
35. Farmer AJ, Brockbank KJ, Keech ML, England EJ, Deakin CD. Incidence and costs of severe hypoglycaemia requiring attendance by the emergency medical services in South Central England. Diabet Med. 2012;29:1447-1450.
36. Beuhler MC, Spiller HA, Aleguas A. Demographics and outcome of unintentional insulin overdoses managed by three poison centers. Clin Toxicol (Phila). 2013;51:789-793.
37. Division of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention. Diabetes data & trends: data from the National Emergency Department Samples, Agency for Healthcare Research and Quality-diabetesrelated hospital and ED visits. Available at: http://www.cdc.gov/diabetes/statistics/emergency- national.htm. Updated September 28, 2012. Accessed March 19, 2015.